BFSG LLC’s VYNE Therapeutics VYNE Stock Holding History

BFSG LLC’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,500	Closed	-$11.7K	–	712
2024 Q4	$11.7K	Buy	+3,500	New	+$9.16K	﹤0.01%	489

Other funds holding VYNE

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

BFSG LLC's VYNE Position: Q1 2025 in Review

BFSG LLC sold out of VYNE Therapeutics (VYNE) in Q1 2025, closing a stake of 3,500 shares — an estimated $11.7K sold.

BFSG LLC first reported a position in VYNE in Q4 2024 and held it in 1 quarter. The position peaked at $11.7K in Q4 2024. 38 funds tracked by Wall St. Rank hold VYNE as of Q1 2025.

BFSG LLC reported no remaining VYNE Therapeutics position as of Q1 2025 after selling out during the quarter.
BFSG LLC sold 3,500 VYNE Therapeutics shares in Q1 2025, an estimated $11.7K.
BFSG LLC first reported a position in VYNE Therapeutics in Q4 2024 and held it in 1 quarter.
BFSG LLC's VYNE Therapeutics position peaked at $11.7K in Q4 2024.
38 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2025.

Based on BFSG LLC's 13F filing for Q1 2025, filed 18 Apr 2025.